Chimeric neutrophils
New patented technology: CAR-neutrophils from pluripotent stem cells
A chemist from Purdue University has proposed an improved method for obtaining "ready—to-use" human immune cells - a strong antitumor agent.
An article about the development was published in the journal Cell Reports (Chang et al., Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy).
Project manager — chemist-technologist Xiaoping Bao recalled that the use of CAR neutrophils (chimeric neutrophils with an antigen receptor) and hematopoietic stem cells is an advanced direction in the treatment of blood diseases and malignant tumors. Neutrophils are the most common leukocyte group of blood cells; they effectively overcome physiological barriers and penetrate tumors. Hematopoietic stem cells are specific progenitor cells that can become any blood cells, including neutrophils, as needed.
"These cells are not easy to obtain for widespread clinical or research use due to the difficulty of multiplying them to the sufficient amount needed for infusion after receiving from donors," says Bao. "Primary neutrophils are particularly resistant to genetic modification, and they have a short life cycle."
Bao and his colleagues have developed and patented a method for the mass production of CAR neutrophils from pluripotent human stem cells; cells that are self-renewing and capable of turning into cells of any type. Pluripotent stem cells are modified so that chimeric antigenic receptors (CAR) are expressed on their surface, and then the cells develop into functional CAR neutrophils - a detailed (special and patented) chemical protocol has been developed for this.
"We have developed a robust protocol for the mass production of de novo neutrophils from human pluripotent stem cells," says Bao. "These neutrophils derived from hematopoietic stem cells have demonstrated excellent and specific antitumor activity against glioblastoma after engineering using chimeric antigen receptors."
Bao, together with the Technology Commercialization Department of the Purdue Research Foundation, applied for an international patent for the development and offered cooperation to the company Life Sciences, part of Google's Alphabet holding.
"We will also work with the doctor Timothy Bentley (Timothy Bentley), a professor of neurology and neurosurgery, and his team at Purdue College of Veterinary Medicine on conducting clinical trials on domestic dogs with spontaneous glioma," promises Bao.
Portal "Eternal youth" http://vechnayamolodost.ru